Black Diamond Therapeutics Opens Well Above IPO Price

Black Diamond Therapeutics BDTX made its public debut Thursday morning, opening at $33 after being priced at $19 per share.

The company listed its shares on the Nasdaq under the ticker symbol "BDTX."

Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule and tumor-agnostic therapies.

JPMorgan, Jefferies, and Cowen and company are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager for the offering.

Related links:

TELA Bio Opens Above IPO Price

Health Catalyst Shares Open Above IPO Price